EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures Miami, FL - June 11, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year. Key 30-day outcomes observed in the CGUARDIANS II trial include: Acute device success was achieved in 100% (50/50) of patients; No deaths, strokes, or myocardial infarctions were reported within 30 days; No stent thrombosis was observed within 30 days; Complete stent patency observed at 30 days in evaluable subjects. Dr. Patrick J. Geraghty, professor…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
InspireMD, Inc
NSPRNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description Number ────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release, dated June 11, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Company context
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.